コンテンツへスキップ
Merck
  • In vitro skin irritation assessment becomes a reality in China using a reconstructed human epidermis test method.

In vitro skin irritation assessment becomes a reality in China using a reconstructed human epidermis test method.

Toxicology in vitro : an international journal published in association with BIBRA (2017-02-22)
Nan Li, Yanfeng Liu, Jie Qiu, Lingyan Zhong, Nathalie Alépée, José Cotovio, Zhenzi Cai
要旨

The in vitro EpiSkin™ test method was validated in 2007 by the European Union Reference Laboratory for alternatives to animal testing (EURL ECVAM) as a full replacement method for the Draize acute skin irritation test and adopted in the OECD Test Guideline 439 in 2009. Based on the EpiSkin™ technology, the production of a reconstructed epidermis model has been established and standardized in China. The evaluation of the in vitro skin irritation test method using this EpiSkin™ model produced in China was performed on a set of 45 chemicals. Good predictive capacity was obtained with 94% (n=17) for sensitivity, 75% (n=28) for specificity and 82% for accuracy. The accuracy of the included 20 OECD reference chemicals also met the OECD acceptance criteria, indicating that this testing method based on the EpiSkin™ model produced in China can be used as a stand-alone test method to predict skin irritation. The availability and validity of in vitro epidermis model and testing method are of great significance for extending the applications of non-animal alternative testing methods in China.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ジプロピレングリコール, 99%, mixture of isomers
Sigma-Aldrich
cis-13-ドコセノアミド
Sigma-Aldrich
酪酸ヘプチル, ≥98%, FG
Sigma-Aldrich
1-ブロモ-4-クロロブタン, 99%
Sigma-Aldrich
2-Chloromethyl-4-methoxy-3,5-dimethylpyridine hydrochloride, 98%
Sigma-Aldrich
3-メルカプト-1-ヘキサノール, AldrichCPR